ASCEND-4 is an open-label, randomized, phase III trial that compared the efficacy and safety of ceritinib- and platinum-based chemotherapy in patients with ALK translocation-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.